Digital 6 critical success factors for a rapid first commercial laun... The success of any drug launch begins long before a regulatory agency gives the product the green light.
Partner Content Partner Content 6 critical success factors of a successful rapid first comme... Annemarie Armstrong shares key factors for rapid launch
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
